Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.64 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136405 | 0.99 | HRH3 (0.66) | HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL3657328 | 0.87 | HRH3 (0.66) | HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL1507123 | 0.86 | HRH3 (0.63) | HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL3068520 | 0.82 | HRH3 (0.77) | HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL2908679 | 0.80 | HRH3 (0.53) | HRH3KCNH2 | |
| SCHEMBL3065883 | 0.80 | HRH3 (0.70) | HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL3082452 | 0.79 | HRH3 (1.00) | HRH3KCNH2 | |
| SCHEMBL2967406 | 0.79 | HRH3 (0.60) | HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL3070211 | 0.78 | HRH3 (1.00) | HRH3KCNH2 | |
| SCHEMBL3077155 | 0.78 | HRH3 (1.00) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883776-B2 | Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-11-11 | — | — | US | disclosed |
| US-20090131415-A1 | CYCLOALKYLOXY-AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131415-A1 | CYCLOALKYLOXY-AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | HRH3 1/4885KCNH2 1285/4885L3MBTL3 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.